Strasbourg, France – Montreal, Canada, January 5, 2023 – Domain Therapeutics (“Domain” or “the Company”), a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in ...
Trial builds on positive Phase 1 study that showed DT-101 was well tolerated and demonstrated target engagement Cardiff, United Kingdom – 2 October 2025 – Draig Therapeutics (“Draig”), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results